Bavituximab: Phase Ib/IIa started

Peregrine said investigators began an open-label, U.S. Phase Ib/IIa trial to evaluate 3 mg/kg IV bavituximab weekly plus 25 mg/m 2 IV Jevtana cabazitaxel given every 3 weeks in a 21-day cycle for up ...